CTLA4 and gastric cancer: Currently, available ICIs for gastric cancer include inhibitors of PD-1 and its ligand (PD-L1), which block the interaction that typically suppresses T-cell activity, as well as inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).